{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T18:24:14Z","timestamp":1750875854211,"version":"3.40.5"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Calcium Disorders clinic McMaster University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00774-025-01585-z","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T01:39:15Z","timestamp":1742693955000},"page":"193-202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Methodology for the international working group clinical practice guidelines on X-linked hypophosphatemia in children and adults"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5378-5548","authenticated-orcid":false,"given":"Dalal S.","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-8956","authenticated-orcid":false,"given":"Aliya A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-4208","authenticated-orcid":false,"given":"Reza D.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-127X","authenticated-orcid":false,"given":"Natasha M.","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-6768","authenticated-orcid":false,"given":"Thomas O.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-3936","authenticated-orcid":false,"given":"Catherine","family":"Chaussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-3467","authenticated-orcid":false,"given":"Erik A.","family":"Imel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-7732","authenticated-orcid":false,"given":"Suzanne M. Jan","family":"de Beur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5936-3146","authenticated-orcid":false,"given":"Pablo","family":"Florenzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archibald","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-3237","authenticated-orcid":false,"given":"Hajar Abu","family":"Alrob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-7894","authenticated-orcid":false,"given":"R. Todd","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9426-9702","authenticated-orcid":false,"given":"Farah","family":"Alsarraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-9217","authenticated-orcid":false,"given":"Signe Sparre","family":"Beck-Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-3970","authenticated-orcid":false,"given":"Martin","family":"Biosse-Duplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-8258","authenticated-orcid":false,"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-4117","authenticated-orcid":false,"given":"Rachel K.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1759-8419","authenticated-orcid":false,"given":"Karel","family":"Dandurand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1891-6765","authenticated-orcid":false,"given":"Guido","family":"Filler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-3469","authenticated-orcid":false,"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9623-962X","authenticated-orcid":false,"given":"Claudia","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-1407","authenticated-orcid":false,"given":"Paul","family":"Goodyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1793-4603","authenticated-orcid":false,"given":"Corinna","family":"Grasemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-7741","authenticated-orcid":false,"given":"Chelsey","family":"Grimbly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-4822","authenticated-orcid":false,"given":"Salma","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-0048","authenticated-orcid":false,"given":"Muhammad K.","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-303X","authenticated-orcid":false,"given":"Sarah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-7947","authenticated-orcid":false,"given":"Aneal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0636-123X","authenticated-orcid":false,"given":"Anna","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3953","authenticated-orcid":false,"given":"Willem F.","family":"Lems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-9587","authenticated-orcid":false,"given":"E. Michael","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-5873","authenticated-orcid":false,"given":"Ciara","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9271-0379","authenticated-orcid":false,"given":"Emmett","family":"Morgante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2054-6898","authenticated-orcid":false,"given":"Anthony A.","family":"Portale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-5638","authenticated-orcid":false,"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8366-8625","authenticated-orcid":false,"given":"Heide","family":"Siggelkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8827-9883","authenticated-orcid":false,"given":"Laura","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-9185","authenticated-orcid":false,"given":"Leanne M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-5718","authenticated-orcid":false,"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"1585_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926","journal-title":"BMJ"},{"key":"1585_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl J, Post PN, Kunz R, Brozek J (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66:719\u2013725","journal-title":"J Clin Epidemiol"},{"key":"1585_CR3","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","volume":"66","author":"JC Andrews","year":"2013","unstructured":"Andrews JC, Sch\u00fcnemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D, Montori VM, Brito JP, Norris S, Elbarbary Mahmoud, Post P, Nasser M, Shukla V, Jaeschke R, Brozek J, Djulbegovic B, Guyatt G (2013) GRADE guidelines: 15 Going from evidence to recommendation\u2014determinants of a recommendation\u2019s direction and strength. J Clin Epidemiol 66:726\u2013735","journal-title":"J Clin Epidemiol"},{"key":"1585_CR4","unstructured":"Guyatt G BJ. Methods Commentary: Risk of Bias in Randomized Trials 1. 2011; Available from: https:\/\/www.distillersr.com\/resources\/methodological-resources\/risk-of-bias-commentary"},{"key":"1585_CR5","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. The Lancet 393:2416\u20132427","journal-title":"The Lancet"},{"key":"1585_CR6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","volume":"108","author":"R Padidela","year":"2021","unstructured":"Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM et al (2021) Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with x-linked hypophosphatemia. Calcif Tissue Int 108:622\u2013633","journal-title":"Calcif Tissue Int"},{"key":"1585_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G et al (2013) GRADE guidelines: 12. preparing summary of findings tables-binary outcomes. J Clin Epidemiol 66:158\u2013172","journal-title":"J Clin Epidemiol"},{"key":"1585_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, Johnston BC, Karanicolas P, Akl EA, Vist G, Kunz R, Brozek J, Kupper LL, Martin SL, Meerpohl JJ, Alonso-Coello P, Christensen R, Schunemann HJ (2013) GRADE guidelines: 13. preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol 66:173\u2013183","journal-title":"J Clin Epidemiol"},{"key":"1585_CR9","doi-asserted-by":"publisher","first-page":"dgae890","DOI":"10.1210\/clinem\/dgae890","volume":"23","author":"DS Ali","year":"2024","unstructured":"Ali DS, Mirza RD, Alsarraf F, Hussein S, Abu Alrob H et al (2024) Systematic review: efficacy of medical therapy on outcomes important to adult patients with X-Linked hypophosphatemia. J Clin Endocrinol Metab 23:dgae890. https:\/\/doi.org\/10.1210\/clinem\/dgae890","journal-title":"J Clin Endocrinol Metab"},{"key":"1585_CR10","doi-asserted-by":"publisher","first-page":"dgaf011","DOI":"10.1210\/clinem\/dgaf011","volume":"9","author":"DS Ali","year":"2025","unstructured":"Ali DS, Mirza RD, Hussein S, Alsarraf F, Alexander RT et al (2025) Systematic review: efficacy of medical therapy on outcomes important to pediatric patients with X-Linked hypophosphatemia. J Clin Endocrinol Metab 9:dgaf011. https:\/\/doi.org\/10.1210\/clinem\/dgaf011","journal-title":"J Clin Endocrinol Metab"},{"key":"1585_CR11","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/jbmr.4698","volume":"37","author":"S Van Uum","year":"2022","unstructured":"Van Uum S, Shrayyef M, M\u2019Hiri I, Dandurand K, Ali DS, Bilezikian JP, Collins MT, Mannstadt M, Rubin MR, Siggelkow H, Tobacco G (2022) Initial assessment and monitoring of patients with chronic hypoparathyroidism: a systematic current practice survey. J Bone Miner Res 37:2630\u20132641","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01585-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-025-01585-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01585-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T17:26:41Z","timestamp":1747675601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-025-01585-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1585"],"URL":"https:\/\/doi.org\/10.1007\/s00774-025-01585-z","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"type":"print","value":"0914-8779"},{"type":"electronic","value":"1435-5604"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Steering Committee: DSA: none; AAK: Speaker, advisory board (Alexion, Amgen); Speaker, advisory board, research funding (Ascendis); Advisory board, research funding (Takeda); Research funding (Amolyt, Calcilytix); RM: none; NMA: Kyowa Kirin, UCB and Amgen (Consulting & advisory boards), XLH-Network Netherlands (Patient Advisory Org), Kyowa Kirin, UCB (unrestricted research grant); MLB: Honoraria: Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB; Grants and\/or speaker: Abiogen, Alexion, Amgen, Amolyt, Amorphical, Bruno Farmaceutici, CoGeDi, Echolight, Eli Lilly, Enterabio, Gedeon Richter, Italfarmaco, Kyowa Kirin, Menarini, Monte Rosa, SPA, Takeda, Theramex, UCB; Consultant: Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Echolight, Kyowa Kirin, Personal Genomics, UCB; TOC: Consulting and advisory boards: Ultragenyx, Kyowa Kirin; Consulting: Viridian; Research support: Ultragenyx; Other roles: Assoc. Editor JBMR, President Ped Endo Soc, Author UpToDate (royalties), XLH-Network (Patient Advisory Org); CC: Institutional research contracts with Kyowa-Kirin and novonordisk; EAI: Ultragenyx (Research funding and consulting), Kyowa Kirin (research funding and consulting), Inozyme (consulting), Amgen (research funding); SJdB: participation in clinical trials and consulting for Ultragenyx and consulting for Kyowa Kirin; PF: Institutional Research Grants: Ultragenyx. Advisory Boards: Ultragenyx, Kyowa Kirin; AM: none; HAA: none; GG: none. Members of the IWG: RTA: Ardylex Inc. (Research grant), Ardylex Inc, Advicienne and Ultragenyx (Consultancy); FA: none; SSBN: Kyowa Kirin (Research grants\/consultancy\/speaker\/ad. board), Inozymes (consultancy), Novo Nordisk (Consultancy); MBD: Kyowa Kirin (research grants, speaker fee), Alexion (speaker fee and advisory board); MCS: Kyowa Kirin (research grants, speaker fee); RKC: speaker and consultancy fees from Kyowa Kirin, advisory to UCB \/ Amgen; KD: Speaker: Amgen, Kyowa Kirin, Mantra Pharma; GF: Consultant: Kyowa Kirin, ProKidney, Ultragenyx, Alnylum, Speaker: ProKidney, Ultragenyx; SF: Kyowa Kirin (consulting); CG: Ascendis Pharma, Takeda and Shire (research funding); PG: none; CoG: Kyowa Kirin; Biomarin, Alexion, Merck, Novo Nordisk; ChG: Ultragenyx (unrestricted research grant, consultancy and advisory board), IPSEN, Alexion and Kyowa Kirin (consultancy); SH: none; MKJ: funding for consultancy and speaker fees from Kyowa Kirin unrelated to this manuscript; SK: Amgen: honoraria\/advisory board, Sandoz Pharmaceuticals: honoraria\/advisory board, PI for XLH disease monitoring program\u2014funded by Ultragenyx, Co-investigator TransconPTH trial funded by Ascendis; AK: none; AL: Consulting (advisory boards): Sanofi-Genzyme, Horizon, Spark Therapeutics, Ultragenyx, Biomarin, Takeda-Shire, Amicus, Recordati, Alexion; Travel grant: Sanofi Genzyme; Research and education grants: Takeda, Sanofi, Amicus; WFL: Speakers fee\/advisory Boards: UCB, Amgen, Galapagos, Pfizer; EML: Consulting: Amgen; Speaker: Amgen, Ascendis; Investigator: Amgen, Ardius, Ultragenyx; CM: Consultancy, Travel\/Research Grants or Advisory boards\u2014 Kyowa Kirin, Ascendis Pharma, Pfizer, Novo Nordisk, Biomarin, Regeneron; EM: none; AAP: Kyowa Kirin (advisory board, speaker); YR: Speaker: Amgen, Dawoong; Investigator: Amgen, Kyowa Kirin, Dongguk, Dong-A, Daewoong; HS: Advisory boards and\/or speaker fees: Amgen, Takeda, UCB, Kyowa Kirin, Merck\/Serono, Alexion, Biomarin. Research grant: Takeda, Ascendis; LT: clinical trial fees from Ultragenyx, NIH and PCOR grants, committees member for the Osteogenesis Imperfecta Foundation, the American Orthopaedic Association and the FDA; LMW: supported by a Tier 1 (Senior) Research Chair in Pediatric Bone Disorders from the University of Ottawa and the Children\u2019s Hospital of Eastern Ontario Research Institute; declares participation in clinical trials with Ultragenyx, and consultancy to Kyowa Kirin and Ultragenyx, and unrestricted educational grants from Ultragenyx and Kyowa Kirin (with funds to Dr. Ward\u2019s institution).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}